Major histocompatibility complex class ii+b7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice

Journal of Experimental Medicine

Volumn 181, Issue 2, 1995, Pages 619-629

  Baskar, Sivasubramanian ^a   Glimcher, Laurie ^b   Nabavi, Nasrin ^c   Jones, Raymond T ^d   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMAL; CELLS, CULTURED; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY; MALE; MICE; MICE, NUDE; SARCOMA, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSFECTION; VACCINES, SYNTHETIC;

EID: 0028898598     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.181.2.619     Document Type: Article

References (30)

1. Pardoll, D. 1993. New strategies for active immunotherapy with genetically engineered tumor cells. Curr. Opin. Immunol. 4: 719-725.
2. Chen, L., S. Ashe, W. Brady, I. Hellstrom, K. Hellstrom, J. Ledbetter, P. McGowan, and P. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102.
3. Townsend, S., and J. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Wash. DC). 259: 368-370.
4. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. Nadler, G. Freeman, and L. Glimcher 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA. 90: 5687-5690.
5. Mueller, D., M. Jenkins, and R. Schwartz. 1989. Clonal expansion versus functional clonal inactivation. Annu. Rev. Immunol. 7: 445-480.
6. Ostrand-Rosenberg, S., A. Thakur, and V. Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144: 4068-4071.
7. Nabavi, N., G. Freeman, A. Gault, D. Godfrey, L. Nadler, and L. Glimcher. 1992. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature (Lond.). 360: 266-268.
8. Oi, V., P. Jones, J. Goding, L. Herzenberg, and L. Herzen-berg. 1978. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and la antigens. Cun. Top. Microbiol. Immunol. 81: 115-120.
9. Wilde, D., P. Marrack, J. Kappler, D. Dialynis, and F. Fitch. 1983. Evidence implicating L3T4 in class II MHC antigen reactivity: monoclonal antibody GK1.5 blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131: 2178-2183.
10. Sarmiento, M., A. Glasebrook, and F. Fitch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell mediated cytolysis in the absence of complement. J. Immunol. 125: 2665-2672.
11. Ozato, K., and D. Sachs. 1981. Monoclonal antibodies to mouse MHC antigens. J. Immunol. 126: 317-321.
12. Ostrand-Rosenberg, S., C. Roby, and V. Clements. 1991. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol. 147: 2419-2422.
13. Azuma, M., M. Cayabyab, J. Phillips, and L. Lanier. 1993. Requirements for CD28-dependent T cell-mediated cytotoxicity. J. Immunol. 150: 2091-2101.
14. Harding, F., and J. Allison. 1993. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J. Exp Med. 177: 1791-1796.
15. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90: 3539-3543.
16. Tahara, H., H. Zeh, W. Storkus, I. Pappo, S. Watkins, U. Gu-bler, S. Wolf, P. Robbins, and M. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189.
17. Tsai, J., B. Gansbacher, L. Tait, F. Miller, and G. Heppner. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Cancer Inst. (Bethesda). 85: 546-553.
18. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421-428.
19. Golumbek, P., A. Lazenby, H. Levitsky, E. Jaffee, H. Karasuyama, M. Baker, and D. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interluekin-4. Science (Wash. DC). 254: 713-716.
20. Connor, J., R. Bannerji, S. Saito, W. Heston, W. Fair, and E. Gilboa. 1993. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp Med. 177: 1127-1134.
21. Chen, L.P., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K.E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179: 523-532.
22. Baskar, S., V. Azarenko, E. Garcia Marshall, E. Hughes, and S. Ostrand-Rosenberg. 1994. MHC class Il-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell. Immunol. 155: 123-133.
23. Galvin, F., G. Freeman, Z. Razi-Wolf, W. Hall, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J. Immunol, 149: 3802-3808.
24. Chen, P., and H. Ananthaswamy. 1993. Rejection of K1735 murine melanoma in syngeneic hosts requires expresssion of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151: 244-255.
25. Lamouse-Smith, E., V. Clements, and S. Ostrand-Rosenberg. 1993. β2M-/-knockout mice contain low levels of CD8+ cytotoxic T lymphocytes that mediate specific tumor rejection. J. Immunol. 151: 6283-6290.
26. + cytotoxic T lymphocytes in(32 microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells. J. Immunol. 152: 2087-2097.
27. Liu, Y., and C. Janeway. 1992. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA. 89: 3845-3849.
28. Nuchtern, J., W. Biddison, and R. Klausner. 1990. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature (Lond.). 343: 74-76.
29. Jacobson, S., R. Sekaly, C. Jacobson, H. McFarland, and E. Long. 1989. HLA class ITrestricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J. Virol. 63: 1756-1762.
30. Jaraquemada, D., M. Marti, and E.O. Long. 1990. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. j. Exp. Med. 172: 947-954.